Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/44
A61K-031/40
C07D-491/00
C07D-487/00
출원번호
US-0974049
(2004-10-25)
발명자
/ 주소
Salvati,Mark E.
Balog,James Aaron
Pickering,Dacia A.
Giese,S?ren
Fura,Aberra
Li,Wenying
Patel,Ramesh N.
Hanson,Ronald L.
Mitt,Toomas
Roberge,Jacques Y.
Corte,James R.
Spergel,Steven H.
R
출원인 / 주소
Bristol Myers Squibb Company
인용정보
피인용 횟수 :
6인용 특허 :
105
초록
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
대표청구항▼
What we claim is: 1. A compound of the formula: wherein R 1 is selected from alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, and aryl or substituted aryl; or a pharmaceutically acceptable salt, solvate, pro
What we claim is: 1. A compound of the formula: wherein R 1 is selected from alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, and aryl or substituted aryl; or a pharmaceutically acceptable salt, solvate, prodrug or stereolsomer thereof. 2. A compound having the formula, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof. 3. A compound having the formula, wherein R7 is NHSO2(C1-4alkyl), or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof. 4. A compound according to claim 3, wherein R7 is-NHSO2(CH2CH3). 5. A pharmaceutical composition comprising one or more compounds according to claim 3, in a pharmaceutically-acceptable carrier or diluent. 6. A compound having the formula, 7. A compound having the formula, 8. The pharmaceutical composition of claim 5, further comprising another anti-cancer agent. 9. The pharmaceutical composition of claim 8, wherein the one or more compounds is the compound (3aα,4β,5α,7β, 7aα)-4-(Octahydro-5-alkylsulfonamido4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-(trifluoromethyl)benzonitrile, or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof. 10. A pharmaceutical composition comprising the compound according to claim 6 in a pharmaceutically-acceptable carrier or diluent. 11. The pharmaceutical composition of claim 10, further comprising another anti-cancer agent. 12. A method for treating a condition or disorder comprising administering to a mammalian species in need thereof a therapeutically effective amount of at least one compound of the following formula: wherein R7 is NHSO2(C1-4alkyl); or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof; wherein said condition or disorder is selected from the group consisting of benign prostate hypertrophia, adenomas and neoplasies of the prostate, heart disease, hirsutism, acne, hyperpilosity, seborrhea, endometriosis, polycystic ovary syndrome, androgenic alopecia, hypogonadism, osteoporosis, suppressing spermatogenisis, libido, cachexia, anorexia, inhibition of muscular atrophy in ambulatory patients, androgen supplementation for age related decreased testosterone levels in men, prostate cancer, breast cancer, endometrial cancer, hot flashes, vaginal dryness, menopause, amenorrhea, dysmenorrhea, contraception, pregnancy termination, cancers containing the progesterone receptor, endometriosis, cachexia, menopause, cyclesynchrony, meniginoma, fibroids, labor induction, psychotic disorders, drug dependence, non-insulin dependent Diabetes Mellitus, dopamine receptor mediated disorders, congestive heart failure, and disregulation of cholesterol homeostasis. 13. The method of claim 12, wherein the at least one compound is (3aα,4β,5α,7β,7aα)-4-(Octahydro-5-ethylsuifonamido-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-(trifluoromethyl)benzonitrile, or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof. 14. The method of claim 12, wherein said condition or disorder is prostate cancer and the at least one compound is (3aα, 4β,5α,7β,7aα)-4-(Octahydro-5-ethylsulfonamido-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-(trifluoromethyl)benzonitrile, or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (105)
Pinto, Donald Joseph Philip; Galemmo, Jr., Robert Anthony; Orwat, Michael James; Quan, Mimi Lifen, 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors.
Poss Michael A. (Lawrenceville NJ) Pansegrau Paul D. (E. Windsor NJ) Wang Shaopeng (E. Windsor NJ) Thottathil John K. (Robbinsville NJ) Singh Janak (Lawrenceville NJ) Mueller Richard H. (Ringoes NJ), 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and.
Moguilewsky Martine (Paris FRX) Bouton Marie M. (Paris FRX), Application of 1-(3′-trifluoromethyl-4′-nitrophenyl)-4,4′-dimethylimidazoline 2,5-dione in the treatment of hormone-d.
Vincent Michel (Bagneux FRX) Remond Georges (Versailles FRX) Laubie Michel (Vaucresson FRX), Azabicyclooctane-carboxylic acids and pharmaceutical compositions containing them and antihypertensive use thereof.
Schweikert Hans-Udo (Bonn-Roettgen DEX) Tunn Ulf (Castrup-Rauxel DEX) Senge Theodor (Castrup-Rauxel DEX) Nmann Friedmund (Berlin DEX), Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperpla.
Lubowitz Hyman R. (Rolling Hills Estates CA) Sheppard Clyde H. (Bellevue WA) Stephenson Ronald R. (Kirkland WA), Crosslinkable polyamideimide oligomers and a method of preparation.
Lubowtiz Hyman R. (Rolling Hills Estates CA) Sheppard Clyde H. (Post Falls ID), Heterocycle or heterocycle sulfone oligomers with multiple chemically functional end caps.
Wilde, Richard Gerald; Bakthavatchalam, Rajagopal; Beck, James Peter; Arvanitis, Argyrios Georgious, Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
Bentley, Jonathan Mark; Roffey, Jonathan Richard Anthony; Davidson, James Edward Paul; Mansell, Howard Langham; Hamlyn, Richard John; Cliffe, Ian Anthony; Adams, David Reginald; Monck, Nathaniel Juli, Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal application.
Duane D. Miller ; Leonid I. Kirkovsky ; James T. Dalton ; Arnab Mukherjee, Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer.
Miller Duane D. ; Kirkovsky Leonid I. ; Dalton James T. ; Mukherjee Arnab, Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer.
Sekut Les ; Carter Adam ; Ghayur Tariq ; Banerjee Subhashis ; Tracey Daniel E., Methods and compositions for modulating responsiveness to corticosteroids.
Sheppard Clyde H. (Boeing Aerospace Company ; P.O. Box 399 ; M/S 73-09 Seattle WA 98124-2499) Lubowitz Hyman R. (26 Coral Tree Ln. Rolling Hills Estates CA 90274), Methods for making liquid molding compounds using diamines and dicyanates.
Vincent Michel (Bagneux FRX) Remond Georges (Versailles FRX) Portevin Bernard (Elancourt FRX) Herve Yolande (Puteaux FRX) Lepagnol Jean (Chatou FRX) Biton Catherine (Nanterre FRX), New heterocyclic tripeptide compounds.
Claussner Andre,FRX ; Goubet Francois,FRX ; Teutsch Jean,FRX, Optionally substituted phenylimidazolidines, their preparation process and intermediates, their use as medicaments and.
Tesoro Giuliana C. (Dobbs Ferry NY) Sastri Vinod R. (Brooklyn NY) Narang Subash C. (Menlo Park CA), Siloxane-containing polyimide coatings for electronic devices.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.